Hong Kong Stock Market | Baoji Pharmaceutical-B (02659.HK) rose more than 6% in early trading. The world's first synthetic biology recombinant ursodeoxycholic acid BJ044 has been approved for clinical use.

According to the The Wisdom Finance and Economics APP, BeiJi Pharmaceutical-B (02659.HK) surged more than 6% in the morning session, and as of the time of publication, it rose by 5.11% to 20.56 Hong Kong dollars, with a turnover of 6.0433 million Hong Kong dollars.